Group 5C: HR+ Breast Cancer; Clinical Trials; Novel Targets & Therapies; Treatment Resistance



Thursday, June 15
2:00 pm – 3:30 pm Eastern Time (US/New York)


Click Here to Join Zoom Event

Poster #3009 : 

First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy

Poster author Erika Hamilton, M.D. is also the scientist for this session

Poster #3010:

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer

Poster author Erika Hamilton, M.D. is also the scientist for this session

View Poster PDFs

Mentor: Julia Levine

Julia is a metastatic lobular breast cancer thriver. She is a founding Steering Committee Member of the Lobular Breast Cancer Alliance (LBCA) since its inception in 2016. Her roles are Research and Publications Curator, Metastatic Lead Advocate, and Patient & Research Advocate. She is the metastatic liaison between LBCA and the Metastatic Breast Cancer Project, Living Beyond Breast Cancer, and BreastCancerTrials.org.

She is a member of the Cancer Support Community-L.A. and a peer mentor in the stage 3/4 breast cancer support group since 2013 to the present. She has also been involved as an advocate with Metavivor and GRASP. She has attended the San Antonio Breast Cancer Symposium, Theresa’s Research Foundation MBC Research Conference, Harvard Medical School conferences, and is on the planning committee for the International Invasive Lobular Cancer (ILC) Symposium at University of Pittsburgh.

She participates in research advocacy to advance her knowledge, educate others, and to provide a patient perspective in the development and implementation of studies in both metastatic and lobular breast cancer.

Twitter: @jackel626

Scientist: Erika Hamilton, M.D.

Erika P Hamilton, M.D., cares for patients with breast and gynecologic cancer. As the director of the breast cancer and gynecologic cancer research program at Sarah Cannon Research Institute, she oversees the program and the clinical trial menu for these cancers across the Sarah Cannon network. After receiving an undergraduate degree from Washington and Lee University in Virginia, Dr. Hamilton completed her medical degree and residency from the University of North Carolina in Chapel Hill. She received her fellowship training in hematology and oncology from Duke University in Durham, North Carolina, where she was recognized as a Top 5 Finalist for Duke’s Annual House staff Fellow Teaching Award. She is board certified in internal medicine and oncology. Additionally, she is a partner with Tennessee Oncology, PLLC.

Twitter: @ErikaHamilton9